



Percentage of All Drug Reports Identified as Medetomidine, by U.S. Census region, 2022–2024



Percentage of Medetomidine Reports that Includes Other Drugs, 2022–2024

■ Medetomidine alone ■ Medetomidine with other drugs □ With one drug □ With two drugs □ With three or more drugs



Medetomidine Combinations Since first appearing, Medetomidine and Dexmedetomidine have increasingly appeared in combination with other drugs (left, pie charts). In addition, the number of combinations with only one other drug has also increased (left, bar charts). Xylazine has been a major additive to Fentanyl and Fentanyl-related drugs, but a shift toward including—and even replacing—Xylazine with Medetomidine is now evident (below).

Xylazine (X), Fentanyl & Fentanyl-Related Drugs (F), and Medetomidine (M) Combinations Out of All Xylazine & Medetomidine Combinations, 2022–2024

	F X	F X M	F M
2022	95.59%	0.62%	0.10%
2023	97.08%	0.49%	0.07%
2024	87.84%	2.87%	5.33%

Substances identified by federal, state, and local laboratories are included in the raw counts of drug reports received by NFLIS-Drug. All Medetomidine percentages in this publication include reports of the isomer Dexmedetomidine. Raw counts have not undergone any adjustments to account for laboratory nonresponse. Data for this publication were exported from the NFLIS-Drug database in March 2025 and include only drugs submitted to laboratories between January 1, 2022, and December 31, 2024. Because of the time it takes for a laboratory to analyze seized material and transfer the data to the NFLIS database, the data in this publication do not reflect total counts of drugs submitted to laboratories over the period. Records related to the substances mentioned in this publication can be seen through the searchable public database (DQS) at the NFLIS website: www.nflis.deadiversion.usdoj.gov. More information on NFLIS data limitations can be found in the NFLIS Questions and Answers guide: <https://www.nflis.deadiversion.usdoj.gov/nflisdata/docs/2k17NFLISQA.pdf>.

